Lead Product(s) : Risedronate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Risedronate Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoporosis, Postmenopausal.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 30, 2022
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Actonel (risedronate sodium hydrate) tablet act as inhibits osteoclasts, which is indicated for the treatment of Paget’s disease and treatment and prevention of postmenopausal osteoporosis.
Product Name : Actonel
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2020
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : The New York Community Trust | East River Medical Imaging | Northwell Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Bisphosphonates on OI-Related Hearing Loss
Details : Risedronate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteogenesis Imperfecta.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 05, 2019
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : The New York Community Trust | East River Medical Imaging | Northwell Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Risedronate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoporosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 22, 2013
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Post-menopausal Women Osteoporosis(Phase III)
Details : Risedronate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoporosis, Postmenopausal.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 07, 2013
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Risedronate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoporosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2012
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Alliance for Better Bone Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis
Details : Risedronate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoporosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 05, 2012
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Alliance for Better Bone Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover
Details : Risedronate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoporosis, Postmenopausal.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 29, 2010
Lead Product(s) : Risedronate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
